|
Development and validation of a novel patient-reported outcomes (PRO) measure for symptom burden in patients with cancer and COVID-19 infection. |
|
|
Consulting or Advisory Role - PledPharma |
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Merck (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Bayer (Inst); Genentech (Inst) |
Patents, Royalties, Other Intellectual Property - Bayer License agreement to use the MDASI (M D Anderson Symptom Inventory) (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Guidepoint Global |
Research Funding - Guardant Health (Inst); Philips Healthcare (Inst); Tempus (Inst) |
|
|
Stock and Other Ownership Interests - AstraZeneca; Merck; Moderna Therapeutics; Pfizer; TRACON Pharma |
Consulting or Advisory Role - Daiichi Sankyo |
Research Funding - AADi (Inst); Athenex (Inst); Novartis (Inst); TRACON Pharma (Inst) |
Patents, Royalties, Other Intellectual Property - Author Royalties from Uptodate |
Travel, Accommodations, Expenses - Daiichi Sankyo |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - MedImmune (I) |
Research Funding - Abbvie (I); Amgen (I); Bayer (I); Blueprint Medicines (I); Celgene (I); Exelixis (I); Fujifilm (I); GlaxoSmithKline (I); Incyte (I); Loxo (I); Multivir (I); NanoCarrier (I); Northwest Biotherapeutics (I); Novartis (I); Pfizer (I); Takeda (I) |
Travel, Accommodations, Expenses - Bayer (I); MedImmune (I); Novartis (I); PharmaMar (I) |